TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive In Brief: Carcinogenesis: Does The Promise Justify The Effort? Task Force Attempts To Find Out September 30, 1977